Pharmaceutical intermediates
Irinotecan hydrochloride Intermediates
4 pharmaceutical intermediates for Irinotecan hydrochloride. Indication: Colorectal cancer; Non-Hodgkin lymphoma; Non-small cell lung cancer; Lung cancer; Ovarian cancer.
About Irinotecan hydrochloride
- Originator
- Yakult Honsha Co., Ltd
- Indication
- Colorectal cancer; Non-Hodgkin lymphoma; Non-small cell lung cancer; Lung cancer; Ovarian cancer
- Approved Date
- 08/05/2010
Available intermediates
4 intermediates currently listed for Irinotecan hydrochloride. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 1,4'-bipiperidyl | 4897-50-1 | / | / |
| 1,4'-Bipiperidine-1'-carbonylchloridehydrochloride(1:1) | 143254-82-4 | / | / |
| (S)-10-Hydroxycamptothecin | 19685-09-7 | / | / |
| 7-Ethyl-10-hydroxycamptothecin | 86639-52-3 | / | / |
Building toward Irinotecan hydrochloride?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →